Mostrando 10 resultados de: 10
Filtros aplicados
Publisher
AAPS Advances in the Pharmaceutical Sciences Series(1)
Applied Sciences (Switzerland)(1)
Cancers(1)
Cell and Bioscience(1)
Journal of Alzheimer's Disease(1)
Área temáticas
Enfermedades(8)
Farmacología y terapéutica(8)
Medicina y salud(4)
Fisiología humana(2)
Fisiología y materias afines(1)
Origen
scopus(10)
Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusEpigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
ArticleAbstract: Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the trPalabras claves:3-nitropropionic acid, Epigallocatechin-3-gallate, Huntington's disease, neurodegenerative diseases, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusNanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
ReviewAbstract: Increasing life expectancy has led to an aging population, which has consequently increased the prevPalabras claves:Alzheimer’s disease, Biomarkers, lipid nanoparticles, Metal nanoparticles, nanotechnology, Polymeric nanoparticlesAutores:Antoni Camins, Boada M., Cano A., Duskey J.T., Ettcheto M., García M.L., Marquié M., Ruiz A., Sanchez-Lopez E., Souto E.M.B., Tosi G., Turowski P.Fuentes:scopusNanoparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations
Book PartAbstract: Recent developments in nanotechnology have provided an unprecedented opportunity to improve the prevPalabras claves:lipid nanoparticles, Nanoparticles, Ocular drug delivery, PLGA nanoparticles, Polymeric nanoparticlesAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusMasitinib for the treatment of alzheimer's disease
ArticleAbstract: The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symPalabras claves:Alzheimer's disease, clinical trials, masitinib, mechanism of actionAutores:Antoni Camins, Auladell C., Cano A., Ettcheto M., Folch J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusPharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease
ReviewAbstract: To deeply understand late onset Alzheimer's disease (LOAD), it may be necessary to change the concepPalabras claves:BDNF, dendritic spines, late onset Alzheimer's disease, neuroinflammation, obesity, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Casadesús G., Castro-Torres R.D., Espinosa-Jimenez T., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Sureda F.X., Verdaguer E.Fuentes:scopusLipid nanocarriers for hyperproliferative skin diseases
ReviewAbstract: Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lPalabras claves:Antiproliferative drugs, Hyperproliferative skin diseases, lipid nanoparticles, Liposomes, Skin cancerAutores:Cano A., Chorilli M., de Souza A.L.R., Gremião M.P.D., Karczewski J., Kolenyak Fernanda Dos Santos, Sanchez-Lopez E., Souto E.M.B., Staszewski R., Zielińska A.Fuentes:scopusState of the art on toxicological mechanisms of metal and metal oxide nanoparticles and strategies to reduce toxicological risks
ReviewAbstract: Metal nanoparticles have been extensively investigated for different types of pharmaceutical applicaPalabras claves:Metal nanoparticles, Nanoparticles functionalization, Nanoparticles toxicity, Reactive oxygen speciesAutores:Antoni Camins, Barroso E., Cano A., Espina M., Ettcheto M., García M.L., García-Torra V., Sanchez-Lopez E., Souto E.M.B., Vázquez-Carrera M.Fuentes:scopusSurface functionalization of plga nanoparticles to increase transport across the bbb for alzheimer’s disease
ReviewAbstract: Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that accounts for about 60% of allPalabras claves:Alzheimer’s disease, blood-brain barrier, Brain delivery, Functionalized PLGA nanoparticlesAutores:Amo L.D., Antoni Camins, Cano A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopus